Abstract:Objective: This study aimed to investigate the roles and mechanisms of action of tenofovir alafenamide fumarate (TAF)/tenofovir disoproxil fumarate (TDF) in liver fibrosis treatment.Methods: The effects of TAF/TDF on carbon tetrachloride (CCl4)-induced liver fibrosis in C57BL/6 wild-type or nonstructural protein 5A transactivated protein 9 (NS5ATP9) knockout mice were studied. The differentiation, activation, and proliferation of LX-2 cells after TAF/TDF treatment were tested in vitro. The expression of NS5ATP9 and activities of transforming growth factor-β1 (TGFβ1)/sekelsky mothers against Decapentaplegic Homolog 3 (Smad3) and NF-κB signaling pathways were detected in TAF/TDF-treated mice and LX-2 cells. The genes related to extracellular matrix accumulation were detected in vivo and in vitro after NS5ATP9 silencing or knockout.Results: TAF/TDF significantly inhibited CCl4-induced liver fibrosis in mice and regulated the differentiation, activation, and proliferation of hepatic stellate cells (HSCs). Furthermore, TAF/TDF suppressed the activities of TGFβ1/Smad3 and NF-κB signaling pathways in vivo and in vitro. NS5ATP9 inhibited liver fibrosis through TGFβ1/Smad3 and NF-κB signaling pathways. TAF/TDF upregulated the expression of NS5ATP9 in vivo and in vitro. Finally, TAF/TDF could only show marginly therapeutic effects when NS5ATP9 was silenced and knocked out in vivo and in vitro.Conclusions: TAF/TDF prevented progression and promoted reversion of liver fibrosis through assembling TGFβ1/Smad3 and NF-κB signaling pathways via upregulating the expression of NS5ATP9. TAF/TDF also regulated the differentiation, activation, and proliferation of HSCs. The findings provided strong evidence for the role of TAF/TDF as a new promising therapeutic strategy in liver fibrosis.Funding Statement: This study was supported by the National Natural Science Foundation of China (No. 81470863 and No. 81670547), the National Key Research and Development Program of China (No. 2017YFC0908100 and No. 2017YFC0908104), the Beijing Municipal Administration of Hospitals (XMLX201711 to JC), the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20151701), and the National Science and Technology Major Project 2017ZX10201201-002-004). Support was also provided by the Collaborative Innovation Center of Infectious Diseases and the Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China.Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: All animal experiments were conducted according to the ethical rules.

Knockdown of TXNDC5 alleviates CCL4-induced hepatic fibrosis in mice by enhancing endoplasmic reticulum stress

Wnt5a Promotes Cytokines Production and Cell Proliferation in Human Hepatic Stellate Cells Independent of Canonical Wnt Pathway.

Knockdown of CXCL1 Improves ACLF by Reducing Neutrophil Recruitment to Attenuate ROS Production and Hepatocyte Apoptosis.

NLRC5 Regulates TGF-β1-induced Proliferation and Activation of Hepatic Stellate Cells During Hepatic Fibrosis.

TXNDC5 Plays a Crucial Role in Regulating Endoplasmic Reticulum Activity through Different ER Stress Signaling Pathways in Hepatic Cells

Role of NLRC5 in Progression and Reversal of Hepatic Fibrosis.

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

DCDC2 inhibits hepatic stellate cell activation and ameliorates CCl4-induced liver fibrosis by suppressing Wnt/β-catenin signaling

Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation

Treatment of Cholestatic Fibrosis by Altering Gene Expression of Cthrc1: Implications for Autoimmune and Non-Autoimmune Liver Disease

CXCL6-EGFR-induced Kupffer Cells Secrete TGF-beta 1 Promoting Hepatic Stellate Cell Activation Via the SMAD2/BRD4/C-MYC/EZH2 Pathway in Liver Fibrosis

Hepatocyte-specific Deficiency of Nrf2 Exacerbates Carbon Tetrachloride-Induced Liver Fibrosis Via Aggravated Hepatocyte Injury and Subsequent Inflammatory and Fibrogenic Responses.

CAT1 Silencing Inhibits TGF-β1-induced Mouse Hepatic Stellate Cell Activation in Vitro and Hepatic Fibrosis in Vivo.

TAF and TDF Attenuate Liver Fibrosis Through NS5ATP9, TGFβ1/Smad3, and NF-κB Signaling Pathways

Targeting EIF5A improves liver fibrosis by inhibiting mitochondrial function of hepatic stellate cells

Single-cell RNA sequencing analysis reveals the role of TXNDC5 in keloid formation

Ligustroflavone Ameliorates CCl4-induced Liver Fibrosis Through Down-Regulating the TGF-β/Smad Signaling Pathway.

Transient Receptor Potential Vanilloid-1 (TRPV1) Alleviates Hepatic Fibrosis via TGF-β Signaling

Regulatory Role and Translational Potential of CCL11 in Liver Fibrosis.

Unc-51 Like Autophagy Activating Kinase 1 Knockout Protects Against Carbon Tetrachloride-induced Liver Fibrosis: the Role of Autophagy

DNMT3a-mediated methylation of TCF21/hnRNPA1 aggravates hepatic fibrosis by regulating the NF-κB signaling pathway